PRIVA-PERINDOPRIL ERBUMINE TABLET
Land: Kanada
Tungumál: enska
Heimild: Health Canada
Vara einkenni
(SPC)
01-06-2022
Sum skjöl fyrir þessa vöru eru ekki tiltæk eins og er, þú getur sent beiðni til þjónustu við viðskiptavini okkar og við munum láta þig vita um leið og við getum fengið þau.
Senda beiðni.
Senda beiðni.
Virkt innihaldsefni:
PERINDOPRIL ERBUMINE
Fáanlegur frá:
NORA PHARMA INC
ATC númer:
C09AA04
INN (Alþjóðlegt nafn):
PERINDOPRIL
Skammtar:
2MG
Lyfjaform:
TABLET
Samsetning:
PERINDOPRIL ERBUMINE 2MG
Stjórnsýsluleið:
ORAL
Einingar í pakka:
100
Gerð lyfseðils:
Prescription
Lækningarsvæði:
ANGIOTENSIN-CONVERTING ENZYME INHIBITORS
Vörulýsing:
Active ingredient group (AIG) number: 0127178001; AHFS:
Leyfisstaða:
CANCELLED POST MARKET
Leyfisdagur:
2022-07-25
Vara einkenni
_Priva-PERINDOPRIL ERBUMINE _
_Page 1 of 55 _
PRODUCT MONOGRAPH
PR PRIVA-PERINDOPRIL ERBUMINE
PERINDOPRIL ERBUMINE TABLETS, USP
2 MG, 4 MG AND 8 MG ANGIOTENSIN CONVERTING ENZYME INHIBITOR
NORA PHARMA INC.
1565, Lionel-Boulet Boul.
Varennes, Québec
J3X 1P7
CONTROL NUMBER: 264075
DATE OF PREPARATION:
May 31, 2022
_Priva-PERINDOPRIL ERBUMINE _
_Page 2 of 55 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION ............................................................. 3
SUMMARY PRODUCT INFORMATION
.............................................................................
3
INDICATIONS AND CLINICAL USE
..................................................................................
3
CONTRAINDICATIONS
........................................................................................................
4
WARNINGS AND PRECAUTIONS
......................................................................................
5
ADVERSE REACTIONS
......................................................................................................
13
DRUG INTERACTIONS
......................................................................................................
20
DOSAGE AND ADMINISTRATION
..................................................................................
22
OVERDOSAGE
.....................................................................................................................
24
ACTION AND CLINICAL PHARMACOLOGY
................................................................. 25
STORAGE AND STABILITY
..............................................................................................
28
SPECIAL HANDLING INSTRUCTIONS
............................................................................
28
DOSAGE FORMS, COMPOSITION AND PACKAGING
.................................................. 29
PART II: SCIENTIFIC INFORMATION ...................................................................................
30
PHARMACEUTICAL INFORMATION
.........................................
Lestu allt skjalið
